PUBLICATION
HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis
- Authors
- Pezzotta, A., Gentile, I., Genovese, D., Totaro, M.G., Battaglia, C., Leung, A.Y., Fumagalli, M., Parma, M., Cazzaniga, G., Fazio, G., Alcalay, M., Marozzi, A., Pistocchi, A.
- ID
- ZDB-PUB-220803-6
- Date
- 2022
- Source
- Pharmacological research 183: 106378 (Journal)
- Registered Authors
- Leung, Anskar
- Keywords
- AML, Dymetil sulfoxide D8418 (Sigma), Glasdegib PZ0303 (Sigma), HDAC6, Hedgehog, Roscovitine R7772 (Sigma), TubastatinA hydrochloride SML0044 (Sigma), cyclopamine hydrate C4116 (Sigma), cytarabine PHR1787 (Sigma), primary cilium, zebrafish
- MeSH Terms
-
- Adult
- Animals
- Cell Proliferation
- Hedgehog Proteins*/metabolism
- Hematopoietic Stem Cells
- Histone Deacetylase 6/metabolism
- Histone Deacetylase Inhibitors*/therapeutic use
- Humans
- Leukemia, Myeloid, Acute*/drug therapy
- Leukemia, Myeloid, Acute*/metabolism
- Signal Transduction
- Zebrafish/metabolism
- PubMed
- 35918044 Full text @ Pharmacol. Res.
Citation
Pezzotta, A., Gentile, I., Genovese, D., Totaro, M.G., Battaglia, C., Leung, A.Y., Fumagalli, M., Parma, M., Cazzaniga, G., Fazio, G., Alcalay, M., Marozzi, A., Pistocchi, A. (2022) HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis. Pharmacological research. 183:106378.
Abstract
Aberrant activation of the Hh pathway promotes cell proliferation and multi-drug resistance (MDR) in several cancers, including Acute Myeloid Leukemia (AML). Notably, only one Hh inhibitor, glasdegib, has been approved for AML treatment, and most patients eventually relapse, highlighing the urgent need ti discover new therapeutic targets. Hh signal is transduced through the membrane of the primary cilium, a structure expressed by non-proliferating mammalian cells, whose stabilization depends on the activity of HDAC6. Here we describe a positive correlation between Hh, HDAC6, and MDR genes in a cohort of adult AML patients, human leukemic cell lines, and a zebrafish model of Hh overexpression. The hyper-activation of Hh or HDAC6 in zebrafish drove the increased proliferation of hematopoietic stem and progenitor cells (HSPCs). Interestingly, this phenotype was rescued by inhibition of HDAC6 but not of Hh. Also, in human leukemic cell lines, a reduction in vitality was obtained through HDAC6, but not Hh inhibition. Our data showed the presence of a cross-talk between Hh and HDAC6 mediated by stabilization of the primary cilium, which we detect for the first time in zebrafish HSPCs. Inhibition of HDAC6 activity alone or in combination therapy with the chemotherapeutic agent cytarabine, efficiently rescued the hematopoietic phenotype. Our results open the possibility to introduce HDAC6 as therapeutic target to reduce proliferation of leukemic blasts in AML patients.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping